• Molecular NameKetotifen
  • SynonymKetotifen Fumarate; Ketotifene [INN-French]; Ketotifene fumarate; Ketotifeno [INN-Spanish]; Ketotifenum [INN-Latin]
  • Weight309.433
  • Drugbank_IDDB00920
  • ACS_NO34580-13-7
  • Show 3D model
  • LogP (experiment)N/A
  • LogP (predicted, AB/LogP v2.0)3.28
  • pka8.43
  • LogD (pH=7, predicted)1.69
  • Solubility (experiment)N/A
  • LogS (predicted, ACD/Labs)(ph=7)-2.88
  • LogSw (predicted, AB/LogsW2.0)0.1
  • Sw (mg/ml) (predicted, ACD/Labs)0.01
  • No.of HBond Donors0
  • No.of HBond Acceptors2
  • No.of Rotatable Bonds0
  • TPSA48.55
  • StatusFDA approved
  • AdministrationOral, Eye Drops
  • PharmacologyA second-generation H1-antihistamine/mast cell stabilizer available in two forms. In its ophthalmic form, it is used to treat allergic conjunctivitis, or the itchy red eyes caused by allergies. In its oral form, it is used to prevent asthma attacks.
  • Absorption_value90.0
  • Absorption (description)Ketotifen is absorbed after oral administration.
  • Caco_2N/A
  • Bioavailability60.0
  • Protein binding75.0
  • Volume of distribution (VD)N/A
  • Blood/Plasma Partitioning ratio (D_blood)N/A
  • MetabollsmIt is metabolised by 10-hydroxylation, N-demethylation, and glucuronic acid conjugation.
  • Half life12 h
  • ExcretionIt is excreted in the urine and faeces as unchanged drug and metabolites.
  • Urinary ExcretionN/A
  • CleranceN/A
  • ToxicityAdverse reactions include headaches, conjunctival injection and rhinitis.
  • LD50 (rat)N/A
  • LD50 (mouse)N/A